Special Session - Metabolic Effects of Hormonal Contraceptives in PCOS: Case Presentations
Time:11:15 am - 1:00 pm
Location:Room 2 - San Diego Convention Center
Richard S. Legro, M.D., Penn State University
Needs Assessment and Description
Recent concerns about selective increased risks
for thromboembolic events with specific hormonal
contraceptives, such as oral contraceptive pills containing
drospirenone or with the vaginal hormonal ring, have
underscored the need for providers to be aware of risk
factors for these events. This live course for clinicians
providing contraceptive care to women will cover the
importance of the changes in risk factors with treatment
of hormonal contraceptives, especially in women with
polycystic ovary syndrome (PCOS).
At the conclusion of this session, participants should be able
- Review evidence for increased risk of thromboembolic
events with specific hormonal contraceptive formulation.
- List relative and absolute contraindications to hormonal
contraception that are specific to women with PCOS.
- Discuss the metabolic changes with oral contraceptive
use relevant to women with PCOS.
A 36-year-old woman with PCOS presents for a follow-up
visit. She has a chief complaint of hirsutism, well controlled
on chronic oral contraceptive pill therapy. She smokes less
than 5 cigarettes a day, is not currently on any medications
and has a recent glycohemoglobin level of 6.0%. On
examination today she has a body mass index (BMI) of 41
kg/m2 and blood pressure of 150/105; repeat was 160/100.
After participating in this session, in my practice I will
consider the following to be an unacceptable health risk for
using the oral contraceptive pill in this patient.
- Age ≥ 35 years
- Currently smoking
- Morbid obesity
- Suspected pre-diabetes or diabetes
- Elevated blood pressure
- Not applicable to my area of practice